How Big Brother is helping to fight COVID-19

June 1, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, NHS, coronavirus, feeature, pharma, track and trace

Following the unprecedented disruption created by COVID-19, many governments are increasingly looking at using data from contact-tracing apps to help …

putey

Russia to begin administering anti-viral COVID-19 drug next week

June 1, 2020
Manufacturing and Production, Research and Development, Sales and Marketing COVID-19, Russia, coronavirus, pandemic, virus

Russia will start its roll out of the anti-viral drug Avifavir (favipiravir) to COVID-19 patients next week, according to the …

gilead-sciences

Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020

June 1, 2020
Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab

Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …

clinical_trials

Significant lack of women and minorities involved in clinical trials for cardiometabolic medication, research shows

June 1, 2020
Sales and Marketing cardio, cardiovascular, cvd

Women and minorities, particularly African Americans, continue to be under represented in clinical trials for cardiometabolic medication, according to a …

lynparza

Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer

June 1, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza

Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …

US donates $1 billion to Oxford University’s COVID-19 vaccine in exchange for 300 million doses

June 1, 2020
Sales and Marketing COVID-19, coronavirus

The US has given $1 billion to AstraZeneca to advance the development and production of the vaccine they are creating …

shutterstock_243110086

First ever benefit-risk analysis is “favourable” for remdesivir as COVID-19 treatment

May 29, 2020
Medical Communications, Research and Development COVID-19, DSRU, Gilead, coronavirus, pharma, remdesivir

The UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s …

trialy

Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study

May 29, 2020
Medical Communications Alzheimer's, leukaemia

The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and while having safe and minimal …

top_10_image_2_2

Top Ten most popular articles on Pharmafile.com this week

May 29, 2020
Medical Communications COVID-19, coronavirus, top 10

GlaxoSmithKline features prominently in the news this week, as they pledged to pay a cash bonus of £1,500 to staff …

shutter

MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations

May 29, 2020
Medical Communications, Research and Development Lenvima, keytruda, pharma

MSD has pulled back the curtain on new data from two trials of its anti-PD-1 immunotherapy Keytruda (pemvbrolizmuab) in combination …

fda

FDA advises recall of diabetes drug metformin over carcinogen concerns

May 29, 2020
Medical Communications Carcinogens, MDMA

The FDA has asked that multiple pharmaceutical companies recall the formulations of their diabetes drug metformin after the regulatory body …

gsk_boronia_australia

GlaxoSmithKline commits to the production of one billion doses of COVID-19 vaccine adjuvant in 2021

May 28, 2020
Manufacturing and Production COVID-19, GSK, coronavirus, pharma, vaccines

GlaxoSmithKline has just come forward to commit to the manufacture and distribution of one billion doses of vaccine adjuvant against …

Novartis releases results of MS drug trials weeks ahead of FDA verdict

May 28, 2020
Business Services MS, Novartis

Novartis has revealed clinical trial data from testing its anti-CD20 leukameia drug Arzerra (ofatumumab) in patients with multiple sclerosis (MS). …

bmssyracuseny

BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis

May 28, 2020
Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis

Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …

black_market

European countries reject hydroxychloroquine treatments for COVID-19

May 28, 2020
Business Services COVID-19, coronavirus, hydroxychloroquine

Multiple European countries have rejected the use of hydroxychloroquine in patients suffering from coronavirus, due to a lack of evidence …

malaria_usa

FDA grants marketing approval for US Army’s malaria treatment

May 28, 2020
Business Services Malaria drug, US, US army, US., malaria

The FDA has granted marketing approval for the US Army Medical Research and Development Command’s (USAMRDC) Artesunate for injection, which …

martin_andrews

Evox appoints ex-GSK exec Martin Andrews as new non-Executive Director

May 28, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Evox, GSK, appointment

Evox Therapeutics has named ex-GlaxoSmithKline executive Martin Andrews as its new non-Executive Director, it has emerged.   Andrews has previously …

sergei_svarovsky

Axim Biotechnologies Inc announces Dr Sergei Svarovsky as Chief Scientific Officer of subsidiary Sapphire Biotech

May 27, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Axim Biotechnologies has announced that Dr Sergei Svarovsky will be the new Chief Scientific Officer of its subsidiary Sapphire Biotech. …

fda

FDA approves Sanofi’s Dupixent for children with dermatitis

May 27, 2020
Research and Development Dupixent, Sanofi, atopic eczema

The FDA has approved Sanofi’s Dupixent (dupilumab) for children between ages 6 to 11 with moderate to severe atopic dermatitis. …

The Gateway to Local Adoption Series

Latest content